|
Re: Phase 1 Renal Trial Completed
|
4
|
Resverlogix Corp.
|
Sep 20, 2016 09:04AM
|
|
The BET inhibitor mCRPC papers keep piling up
|
4
|
Zenith Epigenetics
|
Mar 21, 2018 11:33AM
|
|
Re: CANTOS good, but FDA not on board with sub-group analysis
|
4
|
Resverlogix Corp.
|
Dec 14, 2018 03:17PM
|
|
Re: Kelsee has big shoes to fill
|
4
|
Resverlogix Corp.
|
May 30, 2019 08:49PM
|
|
Re: Pfizer's PCSK9 Inhibitor bococizumab - further development being scrapped
|
4
|
Resverlogix Corp.
|
Nov 01, 2016 02:03PM
|
|
Re: BETonMACE Placebo Estimate
|
4
|
Resverlogix Corp.
|
Feb 20, 2019 04:12PM
|
|
Will DM have an interview podcast on Biotech Nation?
|
4
|
Resverlogix Corp.
|
Jun 19, 2015 02:17PM
|
|
Re: ERA-EDTA 2019 Symposium: Vascular calcification in kidney disease: Epigenetics as a novel approach?
|
4
|
Resverlogix Corp.
|
Apr 14, 2019 06:17PM
|
|
Re: Question for scientists
|
4
|
Resverlogix Corp.
|
Nov 23, 2019 07:23AM
|
|
ZEN-3694/Enzalutamid... vs. Enzalutamide alone?
|
4
|
Zenith Epigenetics
|
Apr 05, 2018 05:39PM
|
|
Re: 3 point MACE vs 5 point MACE
|
4
|
Resverlogix Corp.
|
Nov 02, 2018 01:23PM
|
|
Roth Conference March 19th 11:00 AM Fireside Chat
|
4
|
Resverlogix Corp.
|
Mar 07, 2019 12:27PM
|
|
Re: Happy Thanksgiving all....
|
4
|
Resverlogix Corp.
|
Oct 15, 2019 04:03PM
|
|
Re: FXR and liver transaminase related adverse events
|
4
|
Resverlogix Corp.
|
Sep 19, 2018 06:58AM
|
|
Re: CANTOS and CIRT
|
4
|
Resverlogix Corp.
|
Nov 14, 2017 12:32PM
|
|
Re: Upcoming CVOT results
|
4
|
Resverlogix Corp.
|
Apr 14, 2019 10:11PM
|
|
Re: CKD & VCD clarification
|
4
|
Resverlogix Corp.
|
Jun 03, 2019 11:44AM
|
|
Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 24, 2020 12:59PM
|
|
Re: Slight Change of topic
|
4
|
Resverlogix Corp.
|
May 24, 2017 04:45PM
|
|
Re: New research report 5/11/16 by Marcel Wijma, Van Leeuwenhoeck Institute
|
4
|
Resverlogix Corp.
|
May 11, 2016 04:25PM
|
